Literature DB >> 14964455

Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts.

M Rüster1, H Sperschneider, R Fünfstück, G Stein, H J Gröne.   

Abstract

BACKGROUND: The beta-chemokines MCP-1 (CCL2) and RANTES (CCL5) have been shown to play important roles in acute renal transplant rejection (AR) and chronic allograft nephropathy (CAN). The potential relationship of expression of these chemokines, their chemokine receptors CCR1, CCR2, CCR5, and the cell populations of inflammatory infiltrate, histological and clinical diagnoses were investigated in biopsies at the time of AR and compared with biopsies of CAN.
METHODS: In 24 renal transplant biopsies with AR (n = 15) and CAN (n = 9), the expression of MCP-1 and RANTES, their receptors CCR1, CCR2, and CCR5 and the infiltration with monocytes/macrophages and T cells were studied.
RESULTS: As previously described, chemokine and chemokine receptor expression was found mainly in mononuclear cells infiltrating the interstitium and glomeruli. In the tubulointerstitial area and glomeruli the expression of MCP-1, RANTES, and their receptors correlated with an infiltration by monocytes/macrophages. Biopsies with CAN revealed a lower expression of MCP-1, RANTES, CCR1, CCR2 and CCR5 in tubulointerstitial cells, and a significantly lower infiltration with MRP14-positive monocytes/macrophages than biopsies with AR. In AR, MCP-1 and CCR1 showed a lower expression compared to RANTES, CCR2, and CCR5.
CONCLUSIONS: The positive correlation between chemokines and chemokine receptors and infiltrating leukocytes during acute rejection, the lower but detectable expression of MCP-1, RANTES, CCR1, CCR2 and CCR5 in CAN, and the differences in the quantity of expression between the different chemokines and chemokine receptors point to a complex regulation of chemokine expression in renal allografts. Since chemokines are not only involved in inflammation but also in tissue regeneration, this could have impact on the development of CAN.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14964455     DOI: 10.5414/cnp61030

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

1.  Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population.

Authors:  Vibha Singh; Praveen Kumar Jaiswal; Rohit Kapoor; Rakesh Kapoor; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-01-16

2.  Chemokines and their receptors in human renal allotransplantation.

Authors:  Denise J Lo; Tim A Weaver; David E Kleiner; Roslyn B Mannon; Lynn M Jacobson; Bryan N Becker; S John Swanson; Douglas A Hale; Allan D Kirk
Journal:  Transplantation       Date:  2011-01-15       Impact factor: 4.939

3.  Urinary cell transcriptomics and acute rejection in human kidney allografts.

Authors:  Akanksha Verma; Thangamani Muthukumar; Hua Yang; Michelle Lubetzky; Michael F Cassidy; John R Lee; Darshana M Dadhania; Catherine Snopkowski; Divya Shankaranarayanan; Steven P Salvatore; Vijay K Sharma; Jenny Z Xiang; Iwijn De Vlaminck; Surya V Seshan; Franco B Mueller; Karsten Suhre; Olivier Elemento; Manikkam Suthanthiran
Journal:  JCI Insight       Date:  2020-02-27

4.  Allo-specific immune response profiles indicative of acute rejection in kidney allografts using an in vitro lymphocyte culture-based model.

Authors:  Sobhana Mahakur; Biman Saikia; Mukut Minz; Ranjana W Minz; Ritambhra Nada; Shashi Anand; Ashish Sharma; Vivekanand Jha; Neha Joshi; Lekha Goel; Amit Arora; Kusum Joshi
Journal:  Clin Exp Nephrol       Date:  2017-08-28       Impact factor: 2.801

Review 5.  Mechanisms of disease: regulation of RANTES (CCL5) in renal disease.

Authors:  Alan M Krensky; Yong-Tae Ahn
Journal:  Nat Clin Pract Nephrol       Date:  2007-03

6.  Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis.

Authors:  L M McIntosh; J L Barnes; V L Barnes; J R McDonald
Journal:  Clin Exp Immunol       Date:  2008-11-25       Impact factor: 4.330

7.  Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis.

Authors:  Carla Q Feitoza; Giselle M Gonçalves; Patrícia Semedo; Marcos A Cenedeze; Hélady S Pinheiro; Felipe Caetano Beraldo; Oscar Fernando Pavão dos Santos; Vicente de Paula A Teixeira; Marlene A dos Reis; Marilda Mazzali; Alvaro Pacheco-Silva; Niels O S Câmara
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

8.  Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.

Authors:  S S Weigt; R M Elashoff; M P Keane; R M Strieter; B N Gomperts; Y Y Xue; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; D J Ross; J P Lynch; D A Zisman; J A Belperio
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

9.  An in vitro model of antibody-mediated injury to glomerular endothelial cells: Upregulation of MHC class II and adhesion molecules.

Authors:  Nancy A Wilson; James Dylewski; Kenna R Degner; Megan A O'Neill; Shannon R Reese; Luis G Hidalgo; Judith Blaine; Sarah E Panzer
Journal:  Transpl Immunol       Date:  2019-12-27       Impact factor: 1.708

10.  Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells.

Authors:  Elizabeth Grunz-Borgmann; Valeri Mossine; Kevin Fritsche; Alan R Parrish
Journal:  BMC Complement Altern Med       Date:  2015-12-15       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.